Bausch Health operates through five business segments—Salix (gastroenterology), International, Solta Medical (aesthetics), Diversified (specialty pharma), and Bausch + Lomb (eye health). The company has undertaken exchange offers to refinance existing senior secured notes and has issued new 10.00% Senior Secured Notes due 2032, signaling focus on deleveraging. The company completed the acquisition of DURECT Corporation through a tender offer and merger, making DURECT a wholly owned subsidiary.
Cyborg Score Rationale
Bausch Health demonstrates solid fundamentals with strong Q3/Q4 2025 revenue growth, improving profitability, and strategic acquisitions driving medium-term growth. However, elevated debt levels and prior restructuring history temper the outlook. The company's diversified portfolio and recent deleveraging efforts position it for steady improvement.
Top Insights
Strong operational momentum: Q4 2025 consolidated revenues of $2.80B (+9% reported, +6% organic) exceeded expectations, with full-year 2025 revenue of $10.27B
Strategic growth through M&A: Acquisition of DURECT Corporation and expansion of Solta Medical in China's aesthetics market demonstrates growth strategy
Active debt management: Multiple refinancing activities including new 10.00% Senior Secured Notes due 2032 and term loan amendments reduce intermediate-term maturities
Segment performance: Salix and Solta Medical driving Q3 results; Bausch + Lomb showing 7% constant currency Q4 revenue growth with 27% adjusted EBITDA growth
Named Competitors
Vision Care & Eye Health Products — Integrated eye care and vision care products
Gastroenterology Pharmaceuticals — GI and hepatology focused specialty pharma
Aesthetic Medical Devices — Aesthetic and surgical laser systems
Generic Pharmaceuticals — Global generic drug manufacturer
Recent Developments
(Feb 2026) CEO and management team participated in J.P. Morgan Healthcare Conference and Evercore Healthcare Conference
(Feb 2026) Full-year 2025 financial results announced: $10.27B revenue, strong profitability with $179M Q3 net income
(Dec 2025) Exchange offers completed for refinancing of senior secured notes with amended credit agreements
(Nov 2025) Bausch + Lomb spin-off continues as separate entity with strong operational momentum and 27% EBITDA growth
Open the full interactive Bausch Health Companies Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.